Attovia Therapeutics holder discloses major pre-IPO stake
Frazier Life Sciences XI, L.P., together with related entities FHMLS XI, L.P. and FHMLS XI, L.L.C., reports a significant ownership position in Attovia Therapeutics, Inc. as ten percent owners.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Frazier Life Sciences XI, L.P., together with related entities FHMLS XI, L.P. and FHMLS XI, L.L.C., reports a significant ownership position in Attovia Therapeutics, Inc. as ten percent owners. The group holds 1,749,192 shares of Series A-1 Preferred Stock, 1,590,175 shares of Series A-2 Preferred Stock, 1,189,940 shares of Series B Preferred Stock, 961,322 shares of Series C Preferred Stock (each series convertible into Common Stock at an exercise price of $0.0000 per share and automatically converting into the same number of Common shares upon closing of the initial public offering), plus 75,349 shares of Common Stock held directly.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C.
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series A-1 Preferred Stock F2, F1 | -- | -- | -- |
| Holding | Series A-2 Preferred Stock F3, F1 | -- | -- | -- |
| Holding | Series B Preferred Stock F4, F1 | -- | -- | -- |
| Holding | Series C Preferred Stock F5, F1 | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Holdings:
Series A-1 Preferred Stock — 1,749,192 contracts (Direct);
Series A-2 Preferred Stock — 1,590,175 contracts (Direct);
Series B Preferred Stock — 1,189,940 contracts (Direct);
Series C Preferred Stock — 961,322 contracts (Direct);
Common Stock — 75,349 shares (Direct)
Footnotes (5)
- F1. The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.
- F2. The Series A-1 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the initial public offering of the Issuer (the "IPO"), the shares of Series A-1 Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.
- F3. The Series A-2 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series A-2 Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.
- F4. The Series B Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series B Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.
- F5. The Series C Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series C Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.
Key Figures
Series A-1 Preferred underlying shares: 1,749,192
Series A-2 Preferred underlying shares: 1,590,175
Series B Preferred underlying shares: 1,189,940
+3 more
6 metrics
Series A-1 Preferred underlying shares
1,749,192
Shares of Common Stock issuable upon conversion of Series A-1 Preferred Stock
Series A-2 Preferred underlying shares
1,590,175
Shares of Common Stock issuable upon conversion of Series A-2 Preferred Stock
Series B Preferred underlying shares
1,189,940
Shares of Common Stock issuable upon conversion of Series B Preferred Stock
Series C Preferred underlying shares
961,322
Shares of Common Stock issuable upon conversion of Series C Preferred Stock
Common Stock held directly
75,349
Total Common shares reported as directly held
Conversion/exercise price
$0.0000
Per-share exercise price for conversion of each series of Preferred Stock into Common Stock
Key Terms
Series A-1 Preferred Stock, initial public offering, automatically convert, ten percent owner
4 terms
Series A-1 Preferred Stock financial
"The Series A-1 Preferred Stock has no expiration date and is convertible"
Series A-1 preferred stock is a specific class of company shares created in an early financing round that typically gives its holders priority over common shareholders for dividends and money if the company is sold or liquidates. Think of it as a special ticket with upfront privileges — often convertible into ordinary shares and sometimes carrying voting or protective rights — so investors use it to reduce risk and preserve control compared with ordinary stock.
initial public offering financial
"Upon closing of the initial public offering of the Issuer (the "IPO")"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
automatically convert financial
"the shares of Series B Preferred Stock will automatically convert into"
ten percent owner financial
"reportingPersons list each entity as the is_ten_percent_owner"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this ownership report reveal about Attovia Therapeutics (ATTO)?
It shows that entities affiliated with Frazier Life Sciences XI, L.P. are ten percent owners of Attovia Therapeutics, Inc., holding multiple series of convertible preferred stock plus 75,349 shares of Common Stock.
What are the Series A-2, B, and C Preferred holdings in Attovia (ATTO)?
The group holds 1,590,175 Series A-2, 1,189,940 Series B, and 961,322 Series C Preferred shares, each series convertible 1:1 into Common Stock at an exercise price of $0.0000 per share.
When will the preferred stock in Attovia (ATTO) automatically convert to common?
The Series A-1, A-2, B, and C Preferred Stock will automatically convert into Common Stock upon closing of the initial public offering of Attovia Therapeutics, Inc., in the same share amounts shown.
Who ultimately controls the reported Attovia (ATTO) holdings?
The shares are held directly by Frazier Life Sciences XI, L.P.. FHMLS XI, L.P. is its general partner, and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P., reflecting a layered partnership control structure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
